文献速递肺栓塞与肺血管病

左心疾病相关肺动脉高压:第七届世界肺动脉高压研讨会任务组解读

Pulmonary hypertension associated with left heart disease.
PubMed 文献 · Eur Respir J · 2024-10-31

左心疾病(LHD)是肺动脉高压(PH)最常见病因,分为孤立性毛细血管后PH(ipcPH)和混合性毛细血管前后PH(cpcPH)。第七届世界肺动脉高压研讨会PH-LHD任务组回顾了新近随机临床试验,重申不推荐在临床试验之外对PH-LHD使用肺动脉高压靶向治疗,并提示可能有害;建议通过表型分型、细化诊断灰区(PAWP 12-18 mmHg)及新分期系统改善预后。

要点

  • 不推荐在临床试验外对左心疾病相关肺动脉高压使用肺动脉高压靶向治疗。
  • 对PAWP处于12-18 mmHg诊断灰区者,应个体化区分ipcPH与cpcPH。
  • 新PH-LHD分期系统(A-D期)有助于按临床特征和血流动力学分层管理。

核心结论

  • 新近随机临床试验结果支持既往推荐,即不推荐在临床试验之外对左心疾病相关肺动脉高压使用肺动脉高压靶向治疗,并提示可能有害。
  • 更关注表型分型被视为最终改善临床结局的总体策略之一。

研究设计与样本

  • 第七届世界肺动脉高压研讨会PH-LHD任务组回顾了新近报道的随机临床试验,并探讨改善结局的新机会。

主要发现

  • 主要随机临床试验结果强化了既往推荐,即不推荐在临床试验之外对PH-LHD使用肺动脉高压靶向治疗,并提示可能有害。
  • 对肺动脉楔压处于诊断灰区(12-18 mmHg)的患者,个体化区分ipcPH与cpcPH可能改善临床结局。
  • 新开发的PH-LHD分期系统将PH伴随LHD分为四期(A=有风险,B=结构性心脏病,C=症状性心脏病,D=晚期),每期以临床特征、血流动力学和潜在治疗策略的进展为特征。

关键数值与推荐

  • 肺动脉楔压诊断灰区为12-18 mmHg,需在此范围内个体化区分ipcPH与cpcPH。
  • PH-LHD分期系统包含四期:A期有风险、B期结构性心脏病、C期症状性心脏病、D期晚期。

临床怎么用

  • 对左心疾病相关肺动脉高压患者,应避免在临床试验之外使用肺动脉高压靶向治疗。
  • 对PAWP处于12-18 mmHg诊断灰区者,应个体化评估以区分ipcPH与cpcPH。
  • 可结合PH-LHD新分期系统(A-D期)对患者进行分层评估和管理。
  • 应关注二尖瓣和主动脉瓣狭窄、肥厚型心肌病和淀粉样心肌病临床谱中的PH。
  • 在慢性肺病和慢性血栓栓塞性肺疾病患者中应识别左心疾病。

局限性

  • 任务组基于新近随机临床试验和专家讨论提出建议,未报告系统检索范围或样本量等具体方法学细节。
  • 更广泛地让左心疾病患者参与临床研究可能需要务实试验等新方法,并可能受益于下一代分析技术解读结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Left heart disease (LHD) is the most common cause of pulmonary hypertension (PH), which may be classified further as isolated post-capillary (ipcPH) or combined post- and pre-capillary PH (cpcPH). The 7th World Symposium on Pulmonary Hypertension PH-LHD task force reviewed newly reported randomised clinical trials and contemplated novel opportunities for improving outcome. Results from major randomised clinical trials reinforced prior recommendations against the use of pulmonary arterial hypertension therapy in PH-LHD outside of clinical trials, and suggested possible harm. Greater focus on phenotyping was viewed as one general strategy by which to ultimately improve clinical outcomes. This is potentially achievable by individualising ipcPH versus cpcPH diagnosis for patients with pulmonary arterial wedge pressure within a diagnostic grey zone (12-18 mmHg), and through a newly developed PH-LHD staging system. In this model, PH accompanies LHD across four stages (A=at risk, B=structural heart disease, C=symptomatic heart disease, D=advanced), with each stage characterised by progression in clinical characteristics, haemodynamics and potential therapeutic strategies. Along these lines, the task force proposed disaggregating PH-LHD to emphasise specific subtypes for which PH prevalence, pathophysiology and treatment are unique. This includes re-interpreting mitral and aortic valve stenosis through a contemporary lens, and focusing on PH within the hypertrophic cardiomyopathy and amyloid cardiomyopathy clinical spectra. Furthermore, appreciating LHD in the profile of PH patients with chronic lung disease and chronic thromboembolic pulmonary disease is essential. However, engaging LHD patients in clinical research more broadly is likely to require novel methodologies such as pragmatic trials and may benefit from next-generation analytics to interpret results.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Maron BA, Bortman G, De Marco T, et al. Pulmonary hypertension associated with left heart disease. Eur Respir J. 2024. PMID: 39209478. doi:10.1183/13993003.01344-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。